Data Published In PLOS ONE Show Mymetics' HIV-1 Innovative Vaccine Is Safe And Elicits Strong Immunogenicity

Vaccine-induced mucosal antibodies may contribute to reduce sexually transmitted HIV-1 Results from a randomized study published in PLOS ONE(1) this week demonstrate that Mymetic' innovative HIV-1 (Human Immunodeficiency Virus type 1) vaccine is safe and well tolerated and demonstrates a high level of immunogenicity in a Phase I trial involving 24 healthy women. The publication highlights that vaccine-induced mucosal antibodies may contribute to reduce sexually transmitted HIV-1... via Health News from Medical News Today Read More Here..